Emergent BioSolutions' Q3 earnings report drives 20% surge in share price, reflecting market optimism. See why award a ...

The company is not selling any securities under this prospectus and will not receive any of the proceeds from the sale of securities by the ...

Emergent BioSolutions raised its revenue guidance and dropped a going concern warning. Its CEO is billing this next chapter ...

My name is Chris, and I will be your conference operator today. At this time, I would like to welcome everyone to the Q3 2024 ...

Emergent BioSolutions expects a 2024 net loss of $203 million-$183 million, down from the previous loss range of $314 million ...

Avidian Wealth Enterprises LLC cut its stake in shares of Emergent BioSolutions Inc. (NYSE:EBS – Free Report) by 20.4% during ...

EPS: US$2.16 (up from US$5.09 loss in 3Q 2023). Revenue missed analyst estimates by 1.2%. Earnings per share (EPS) exceeded ...

Emergent BioSolutions appointed Dr. Simon Lowry as chief medical officer and head of research and development. CureVac named ...

Emergent Biosolutions ( (EBS) ) has released its Q3 earnings. Here is a breakdown of the information Emergent Biosolutions presented to its ...

Shares of Emergent Biosolutions climbed after the company reported an increase in revenue and swung to a profit in the third quarter. The stock was up 28% to $11.81 in Thursday afternoon trading.

Q3 2024 Earnings Call Transcript November 6, 2024 Emergent BioSolutions Inc. beats earnings expectations. Reported EPS is ...